FDA Announces Proposed Collection of Information for Adverse Experience Reporting

Summary

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, focusing on adverse experience reporting for licensed biological products, as part of its general records collection activities.